{"pmid":32344315,"pmcid":"PMC7195028","title":"N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome.","text":["N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome.","Med Hypotheses","Assimakopoulos, Stelios F","Marangos, Markos","32344315"],"journal":"Med Hypotheses","authors":["Assimakopoulos, Stelios F","Marangos, Markos"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344315","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.mehy.2020.109778","e_drugs":["Acetylcysteine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495062638593,"score":9.490897,"similar":[{"pmid":32322486,"pmcid":"PMC7172861","title":"Intravenous Vitamin C for reduction of cytokines storm in Acute Respiratory Distress Syndrome.","text":["Intravenous Vitamin C for reduction of cytokines storm in Acute Respiratory Distress Syndrome.","The recent outbreak of Covid19 has required urgent treatments for numerous patients. No suitable vaccines or antivirals are available for Covid19. The efficiency against Covid19 of WHO therapies of choice, that are two antivirals developed for other pathologies, is controversial. Therefore, alternative approaches are required. Intravenous (IV) Vitamin C (Vit-C) has emerged as one of the other alternatives for this purpose. Here we review the effects of IV Vit-C on the immune system response, the antiviral properties of IV Vit-C, and finally the antioxidant properties of IV Vit-C to specifically address the cytokines' storm characteristic of the Acute Respiratory Distress Syndrome (ARDS) that occur in the later cycle of the Covid19 infectious disease.","PharmaNutrition","Boretti, Alberto","Banik, Bimal Krishna","32322486"],"abstract":["The recent outbreak of Covid19 has required urgent treatments for numerous patients. No suitable vaccines or antivirals are available for Covid19. The efficiency against Covid19 of WHO therapies of choice, that are two antivirals developed for other pathologies, is controversial. Therefore, alternative approaches are required. Intravenous (IV) Vitamin C (Vit-C) has emerged as one of the other alternatives for this purpose. Here we review the effects of IV Vit-C on the immune system response, the antiviral properties of IV Vit-C, and finally the antioxidant properties of IV Vit-C to specifically address the cytokines' storm characteristic of the Acute Respiratory Distress Syndrome (ARDS) that occur in the later cycle of the Covid19 infectious disease."],"journal":"PharmaNutrition","authors":["Boretti, Alberto","Banik, Bimal Krishna"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32322486","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.phanu.2020.100190","keywords":["antiviral agents","covid19","cytokines","severe acute respiratory syndrome coronavirus","vitamin c"],"e_drugs":["Ascorbic Acid"],"topics":["Treatment"],"weight":1,"_version_":1666138493927030785,"score":63.986286},{"pmid":32376400,"title":"Cytokine storm syndrome in severe COVID-19.","text":["Cytokine storm syndrome in severe COVID-19.","Autoimmun Rev","Ruscitti, Piero","Berardicurti, Onorina","Iagnocco, Annamaria","Giacomelli, Roberto","32376400"],"journal":"Autoimmun Rev","authors":["Ruscitti, Piero","Berardicurti, Onorina","Iagnocco, Annamaria","Giacomelli, Roberto"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376400","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102562","locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097403580416,"score":56.68499},{"pmid":32352407,"title":"Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","text":["Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.","J Clin Invest","Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan","32352407"],"abstract":["Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases."],"journal":"J Clin Invest","authors":["Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352407","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1172/JCI139642","e_drugs":["Catecholamines"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495698075648,"score":55.7351},{"pmid":32456368,"title":"[Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome].","text":["[Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome].","Coronavirus disease 2019 (COVID-19) has become a global public health emergency threatening people's lives around the world. Although the acute respiratory distress syndrome (ARDS) induced by COVID-19 is similar to the ARDS caused by other diseases in terms of pathophysiological basis and clinical manifestations, they are also different in many aspects, which lead to different clinical therapies. Therefore, understanding the differences and similarities of ARDS induced by COVID-19 and other diseases currently are the basis for clinicians to make decisions for the treatment of COVID-19 induced ARDS.","Zhonghua Shao Shang Za Zhi","Pan, C","Xie, J F","Qiu, H B","Yang, Y","32456368"],"abstract":["Coronavirus disease 2019 (COVID-19) has become a global public health emergency threatening people's lives around the world. Although the acute respiratory distress syndrome (ARDS) induced by COVID-19 is similar to the ARDS caused by other diseases in terms of pathophysiological basis and clinical manifestations, they are also different in many aspects, which lead to different clinical therapies. Therefore, understanding the differences and similarities of ARDS induced by COVID-19 and other diseases currently are the basis for clinicians to make decisions for the treatment of COVID-19 induced ARDS."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Pan, C","Xie, J F","Qiu, H B","Yang, Y"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456368","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3760/cma.j.cn501120-20200407-00214","keywords":["acute respiratory distress syndrome","coronavirus disease 2019","immunomodulation","mechanical ventilation","original disease"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668141322611982336,"score":53.423325},{"pmid":32338605,"title":"Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.","text":["Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.","COVID-19 patients can present with pulmonary edema early in disease. We propose that the this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) and B2R on endothelial cells in the lungs. SARS-CoV-2 enters the cell via ACE2 that next to its role in RAS is needed to inactivate des-Arg9 bradykinin, the potent ligand of the bradykinin receptor type 1 (B1). Without ACE2 acting as a guardian to inactivate the ligands of B1, the lung environment is prone for local vascular leakage leading to angioedema. Here we hypothesize that a bradykinin-dependent local lung angioedema via B1 and B2 receptors is an important feature of COVID-19. We propose that blocking the B2 receptor and inhibiting kallikrein activity might have an ameliorating effect on early disease caused by COVID-19 and might prevent acute respiratory distress syndrome (ARDS). In addition, this pathway might indirectly be responsive to anti-inflammatory agents.","Elife","van de Veerdonk, Frank L","Netea, Mihai G","van Deuren, Marcel","van der Meer, Jos Wm","de Mast, Quirijn","Bruggemann, Roger J","van der Hoeven, Hans","32338605"],"abstract":["COVID-19 patients can present with pulmonary edema early in disease. We propose that the this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) and B2R on endothelial cells in the lungs. SARS-CoV-2 enters the cell via ACE2 that next to its role in RAS is needed to inactivate des-Arg9 bradykinin, the potent ligand of the bradykinin receptor type 1 (B1). Without ACE2 acting as a guardian to inactivate the ligands of B1, the lung environment is prone for local vascular leakage leading to angioedema. Here we hypothesize that a bradykinin-dependent local lung angioedema via B1 and B2 receptors is an important feature of COVID-19. We propose that blocking the B2 receptor and inhibiting kallikrein activity might have an ameliorating effect on early disease caused by COVID-19 and might prevent acute respiratory distress syndrome (ARDS). In addition, this pathway might indirectly be responsive to anti-inflammatory agents."],"journal":"Elife","authors":["van de Veerdonk, Frank L","Netea, Mihai G","van Deuren, Marcel","van der Meer, Jos Wm","de Mast, Quirijn","Bruggemann, Roger J","van der Hoeven, Hans"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338605","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7554/eLife.57555","keywords":["human biology","immunology","inflammation","medicine","viruses"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494219583491,"score":53.21067}]}